Immutep's Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026

Immutep's abstract on IMP761 has been accepted for a late-breaking poster presentation at ACR Convergence 2026. The presentation will showcase data from the first-in-human Phase I study of IMP761, which is a first-in-class LAG-3 agonist antibody tested in healthy volunteers.